ArticleExperimental and clinical psychopharmacology2026
App-based contingency management to reduce heavy drinking days among smokers receiving varenicline: Feasibility, acceptability, and efficacy indicators from a phase I analog trial.
Article in Experimental and clinical psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Tobacco and alcohol coaddiction is highly prevalent and represents a substantial challenge for treatment, as addiction to one of these substances leads to a worse prognosis when treating the other. In this pilot study, we evaluated the feasibility, acceptability, and signals of efficacy when incorporating varenicline (VC) and app-based contingency management (CM) to treat tobacco smoking and alcohol use disorders (AUD), concomitantly. Fourteen participants with an AUD who were seeking smoking cessation treatment were exposed to a within-subject A-B-A experimental design lasting 9 weeks. Participants were provided VC for smoking cessation throughout the study. Participants were also instructed to submit five daily breathalyzer samples using a mobile app. During the experimental phase (B), participants could earn reinforcers totaling $15 per day for submitting all breathalyzer samples with results below 0.08. Submitting all five samples on a given day occurred on 75% of study days, with VC adherence occurring on 74% of study days. Participants were retained for an average of 7.6 weeks and most of them (80%) found the app quick to learn and easy to use. A significant reduction of heavy-drinking days (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.